acalabrutinib
astrazeneca
['acalabrutinib', 'marginal zone lymphoma', 'lymphoma']
results from a clinical trial of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma will be presented today at 8 a.m. cst. #asco22 
City of Hope is a National Cancer Institute-designated comprehensive cancer center for cancer, diabetes and other life-threatening diseases.